Prediction of Crohn’s disease relapse with faecal calprotectin in infliximab responders: a prospective study
✍ Scribed by A. R. Deshpande; S. Strobel
- Book ID
- 108606397
- Publisher
- John Wiley and Sons
- Year
- 2011
- Tongue
- English
- Weight
- 55 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0269-2813
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Background: Infliximab is the only medical therapy that has been proven to be effective in fistulizing Crohn's disease (CD), but the recurrence rate of fistulas is high despite maintenance therapy. The aim of this prospective study was to evaluate the short-and long-term efficacy of a combined sched
Background: We examined short-and long-term benefits and safety of infliximab (IFX) in a population-based cohort of Crohn's disease (CD) patients <17 years old at diagnosis. ## Methods: The following parameters were assessed: short-and long-term efficacy of IFX, impact of drug efficacy, and mode